U.S. markets open in 3 hours 57 minutes
  • S&P Futures

    4,401.75
    +52.75 (+1.21%)
     
  • Dow Futures

    34,481.00
    +296.00 (+0.87%)
     
  • Nasdaq Futures

    14,413.75
    +273.00 (+1.93%)
     
  • Russell 2000 Futures

    2,027.90
    +26.60 (+1.33%)
     
  • Crude Oil

    86.06
    +0.46 (+0.54%)
     
  • Gold

    1,847.10
    -5.40 (-0.29%)
     
  • Silver

    23.97
    +0.07 (+0.29%)
     
  • EUR/USD

    1.1285
    -0.0020 (-0.18%)
     
  • 10-Yr Bond

    1.7830
    0.0000 (0.00%)
     
  • Vix

    28.85
    -1.05 (-3.51%)
     
  • GBP/USD

    1.3510
    +0.0004 (+0.03%)
     
  • USD/JPY

    114.1690
    +0.3030 (+0.27%)
     
  • BTC-USD

    37,757.77
    +1,229.99 (+3.37%)
     
  • CMC Crypto 200

    857.67
    +37.09 (+4.52%)
     
  • FTSE 100

    7,500.06
    +128.60 (+1.74%)
     
  • Nikkei 225

    27,011.33
    -120.01 (-0.44%)
     

Is Now An Opportune Moment To Examine Surmodics, Inc. (NASDAQ:SRDX)?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • SRDX

Surmodics, Inc. (NASDAQ:SRDX), might not be a large cap stock, but it saw a decent share price growth in the teens level on the NASDAQGS over the last few months. As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, what if the stock is still a bargain? Let’s take a look at Surmodics’s outlook and value based on the most recent financial data to see if the opportunity still exists.

View our latest analysis for Surmodics

What's the opportunity in Surmodics?

According to my valuation model, Surmodics seems to be fairly priced at around 17.46% above my intrinsic value, which means if you buy Surmodics today, you’d be paying a relatively reasonable price for it. And if you believe that the stock is really worth $48.32, there’s only an insignificant downside when the price falls to its real value. So, is there another chance to buy low in the future? Given that Surmodics’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us an opportunity to buy later on. This is based on its high beta, which is a good indicator for share price volatility.

Can we expect growth from Surmodics?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to more than double over the next couple of years, the future seems bright for Surmodics. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? It seems like the market has already priced in SRDX’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value?

Are you a potential investor? If you’ve been keeping tabs on SRDX, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

So while earnings quality is important, it's equally important to consider the risks facing Surmodics at this point in time. While conducting our analysis, we found that Surmodics has 1 warning sign and it would be unwise to ignore this.

If you are no longer interested in Surmodics, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.